Bleomycin Sulfate

For research use only. Not for use in humans.

目录号:S1214 别名: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate硫酸博来霉素是一种糖肽类抗生素,也是一种鳞状细胞癌(SCC)抗癌剂,在UT-SCC-19A细胞中IC50为4 nM。

规格 价格 库存 购买数量  
RMB 1410.29 现货
RMB 5474.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Bleomycin Sulfate发表文献23篇:

质量管理及产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Bleomycin Sulfate硫酸博来霉素是一种糖肽类抗生素,也是一种鳞状细胞癌(SCC)抗癌剂,在UT-SCC-19A细胞中IC50为4 nM。
体外研究

UT-SCC-12A和 UT-SCC-12B均对Bleomycin sulfate耐药,IC50分别为14.2 nM 和13 nM。[1]肺泡巨噬细胞与0.01 μg/mL到1μg /mL Bleomycin sulfate培养18小时显著比巨噬细胞单独培养分泌更多的成纤维细胞生长因子。Bleomycin sulfate刺激的巨噬细胞持续产生大量成纤维细胞生长因子,即使在移去Bleomycin sulfate,用新鲜培养基(不含Bleomycin sulfate)取代之后,该作用依然存在。Bleomycin sulfate刺激肺泡巨噬细胞导致的纤维素生长因子分泌被环己酰亚胺,和5-脂氧合酶抑制剂NDGA(去甲二氢愈创木酸)和BW755c抑制,表明其不仅需要蛋白质合成,也需要花生四烯酸代谢的5-脂氧合酶途径活性完全表达。[2] Bleomycin sulfate (400 µg/mL)培养24小时,降低NTera-2细胞的活性,增加caspase-3,-8和-9的活性,增加Bax和细胞质细胞色素C水平,并降低Bcl-2水平。[3]对于不稳定性畸变,Bleomycin sulfate对ADIPO-P2细胞的致染色体断裂作用在处理后至少持续10天。此外,暴露于Bleomycin sulfate的细胞处理10天后,端粒融合体的外观表明Bleomycin sulfate能够诱导延迟的端粒失稳。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 NHrue4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK4OlMx6oDVMUCwNEDPxG1? Ml;RNlQhcMLi M3LPZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M17vcVI3ODh6N{Gx
POLK WT NI\SbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFzLkhihKnDueLCiUGuO:Kh|ryP NXHoSm1vOjZyM{G0NFA>
POLK KO M1y0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTRwMERihKnDueLCiUGuPVLDqM7:TR?= NIXYbXozPjB|MUSwNC=>
POLK CD MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;MUmZtUUN3ME21MlU66oDLwsJihKkyNjBywrFOwG0> MXGyOlA{OTRyMB?=
RLE/Abca3 NHe2UotHfW6ldHnvckBCe3OjeR?= M3ztc|AvPMLizszN MYqxOFTDqGh? NVzLe4E3cW6mdXPld{BiKG2xcoDoc4xw\2mlYXygZ4hidmenIH\yc40h\XCrdHjlcIlidC2uaXvlJI1wenCqb3zv[5khfG9iYTD3bYRmNCC|cILlZYQud3W2IH3vdpBpd2yxZ4pCpC=> NFHMNlQzPTd4MEWzPC=>
PMCs M4nQZ2Z2dmO2aX;uJGF{e2G7 M1PDUFAvOeLCk{NCpO69\y:vbB?= NHPlTWszPMLiaB?= MYfjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnPy[YF{\SCrbjD0bIUheHKxdHXpckBt\X[nbDDv[kBkd2yuYXflck1KyqB? Ml[4NlU2QTV4NEK=
PMCs MlixSpVv[3Srb36gRZN{[Xl? NFXUfJoxNjMEoN88[{9udA>? M1W5bFI16oDVN{NCpIg> MofRbY5lfWOnczDpcoNz\WG|ZYOgbY4hfmmvZX70bY4h[W6mIN8xMXNOSSCycn;0[Ylv MXKyOVU6PTZ2Mh?=
PMCs MXrGeY5kfGmxbjDBd5NigQ>? M1PDR|AvOsLizsznM41t MoPOO|IhcA>? NED6NpBqdmS3Y3XzJIRm[3KnYYPld{BqdiCleYTvb4Vz[XSrbj24JIFv\CCHLXPh[IhmemmwIIDyc5RmcW5? MX:yOVU6PTZ2Mh?=
PMCs MnPRSpVv[3Srb36gRZN{[Xl? MV2wMlLDqM7:Zz;tcC=> NG[0XI0yOi9{ND:0PEBp NFnNfIFqdmO{ZXHz[ZMh[2WubDDtbYdz[XSrb36= MkTsNlU2QTV4NEK=
IMR-32 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr6[lRiPy534pkSNVIxKML3Zz;tcC=> NHjjOHcyOuLKkkS4JIg> Mli5TWM2OD14MDFCuYcwdWxiYYSgeIhmKGWwZDDv[kAzPCCqcoOgc4YhcW6ldXLheIlwdg>? M{\E[VI2PTN4M{S1
HT1080 MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxJO69VQ>? M{fUVFI1KGkEoB?= M2q0O4xm[WS|IITvJIEhTzJxTTDk[YxigQ>? MWiyOVUyQDl4MR?=
HT1080 NYXaPIR{TnWwY4Tpc44hSXO|YYm= NXTyelJ6OSEQvF2= MnW0NlQhcMLi NWPJTmprcW6mdXPld{BiKHCxdHXueEBodG:kYXygSG5CKGSjbXHn[UBz\XOyb37z[S=> NHzKdGkzPTVzOEm2NS=>
HDFn NILqVnFEgXSxdH;4bYNqfHliQYPzZZk> NVfWN5VXPzJiaB?= NVf2N|VvUUN3ME25MlMyLcLi MkDhNlUzPzZ5OUK=
THP-1 MXvDfZRwfG:6aXPpeJkhSXO|YYm= MlrJO|IhcA>? Moe2TWM2OD12Lke3KS=> MXSyOVI4Pjd7Mh?=
HT-29 MlXvR5l1d3SxeHnjbZR6KEG|c3H5 MmPFO|IhcA>? NVzFUYZEUUN3ME2xNU41QSV? NEn6TGEzPTJ5Nke5Ni=>
HCT116  NU\1dZZlS3m2b4TvfIlkcXS7IFHzd4F6 M13ISVczKGh? M3XCeGlEPTB;MUGuN|Qm MnTvNlUzPzZ5OUK=
A431 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LrVlUxNTJyMDDJWS=> MlK5OFjjiImq Mof3bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MmDjNlUyODF{OUm=
T24 M2jYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUK1NE0zODBiSWW= M12wclQ56oDLaB?= M1vyTolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NETZNHEzPTFyMUK5PS=>
AY-27  M4DhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWK1NE0zODBiSWW= MlS5OFjjiImq MVjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NEnne3czPTFyMUK5PS=>
A549 NWjVfW5xTnWwY4Tpc44hSXO|YYm= M1HGRVEhyrWpL33MxsA> MUSwMVQ5KGh? NI\MUIZqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4bDqE:STtMgcXJPSQ>? M1e4V|I1QTZ|NkO1
MLE12 Mn3RSpVv[3Srb36gRZN{[Xl? MWOxJOK2\y:vTNMg MkO5NE01QCCq Ml\obY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> NUfiO4xyOjR7NkO2N|U>
Jurkat NWnJV4NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXnTFEzOOLCid88cS=> NX7jVJBuOjUkgJnoxsA> NYmxXYRL[XK{ZYP0d{B1cGViY3XscEBkgWOuZTDheEB1cGViR{KgdIhie2V? NGG5ZXMzPDlzNki5Ny=>
HeLa  M4[wS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDCTWM2OD1zMD6yxsDPxE1? NVm1doNrOjR5M{KzPVc>
C18-4 NWn2e2FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYiwMVExOCEQvF2= M33FR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MYWyOFU4OTl6Mh?=
BMG-1  NWr0foFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPmdos5PDBxOEFCpO69\y:v MUKzxsBp M{f1eIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MWKyN|kxPjd{Nh?=
A459 MVzBdI9xfG:|aYOgRZN{[Xl? NYDt[GJyOTBibWW= M4PkdlQ5KGh? M{PBOIlv\HWlZYOgZZBweHSxc3nz MXqyN|kxOjd4Nh?=
MOCK M{LqRWFxd3C2b4Ppd{BCe3OjeR?= M4T1WFExKG2X MmrHOFghcA>? MoPSbY5lfWOnczDhdI9xfG:|aYO= NVvVNG11OjN7MEK3OlY>
MMP1 MlTqRZBweHSxc3nzJGF{e2G7 NVn2WoJSOTBibWW= Moq2OFghcA>? M{i1U4lv\HWlZYOgZZBweHSxc3nz NVPVV281OjN7MEK3OlY>
A549 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jnUFIxOCEQvF2= MVmyOEBpyqB? NUfzbmdL\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NUX3RY5{OjN6MEW3PVM>
HCT-116 M4fve2Fxd3C2b4Ppd{BCe3OjeR?= NY\HR5ZHOy95LkWvNVUh|rypL33s NFTqNXU1QCCq NX7t[Hh[emWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? M3nPdlI{PzB6Nk[4
HeLa MYPBdI9xfG:|aYOgRZN{[Xl? M1;HOFMwPy53L{G1JO69\y:vbB?= NHTLboY1QCCq NXHncFZoemWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? NGPQXIQzOzdyOE[2PC=>
HCT116 MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX0NE0yODBizsznM41t NXm3ZWU3PDhiaB?= M{fqRYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MoXqNlM2OTh{MEG=
NCM460 NXj4O25tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n6N|AuOTByIN88[{9udA>? MoHVOFghcA>? M2PQV4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NVPO[W5{OjN3MUiyNFE>
NT2  Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHLNlQhcMLi Mn7DUGQ2OD12MEFihKnDvWdxbXy= MYOyN|M5PjR{MB?=
NT2  NXTncFZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVG0PEBp MYfMSFUxRTFyMDFCuYcwdWx? MVuyN|M5PjR{MB?=
NT2  NWrwRWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLyUXI4OiCq MXzMSFUxRTJy4pEJxtVoN22u NYrXb4pIOjN|OE[0NlA>
NT2  M3;SSWFxd3C2b4Ppd{BCe3OjeR?= M2njTVQxOOLCidM1[{9udA>? MX2yOEBpyqB? M{Lqd4lv\HWlZYOgd4lodmmoaXPhcpQhcW6lcnXhd4V{KGmwIHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? MXyyN|M5PjR{MB?=
NTera-2 M2OzSWZ2dmO2aX;uJGF{e2G7 MmToNVIxKM7:Zz;tcC=> NUGy[YZ1PzJiaB?= NVr5S|F6e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> MXGyNlgzPTN3NR?=
NCCIT M2fxT2Z2dmO2aX;uJGF{e2G7 MljWNVIxKM7:Zz;tcC=> M3TodlczKGh? M4DoXpNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz Mn25NlI5OjV|NUW=
NTera-2 Mn;oSpVv[3Srb36gRZN{[Xl? NVe5WXJlOTJyIN88[{9udA>? NFq5NJc4OiCq NX7VSXR2e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ MnW0NlI5OjV|NUW=
NCCIT M4\OO2Z2dmO2aX;uJGF{e2G7 NFzLPXYyOjBizsznM41t NIPFNZY4OiCq Mljud4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiVFLBVnMhdGW4ZXzz MYqyNlgzPTN3NR?=
NCCIT NXfwV251TnWwY4Tpc44hSXO|YYm= MUCxNlAh|rypL33s MY[3NkBp M4TKTJNq\26rZnnjZY51dHliZHXjdoVie2W|IFfTTEBt\X[nbIO= MmDoNlI5OjV|NUW=
NTera-2 M4P0cWZ2dmO2aX;uJGF{e2G7 MorvNVIxKM7:Zz;tcC=> M1GwblczKGh? MVzzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCScn;0[YlvKGOjcnLvcpltKGyndnXsdy=> MYqyNlgzPTN3NR?=
NCCIT NGXsVFVHfW6ldHnvckBCe3OjeR?= M2HZclEzOCEQvHevcYw> NGLZXYQ4OiCq Mn7Ud4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> MXeyNlgzPTN3NR?=
NTera-2 MWjGeY5kfGmxbjDBd5NigQ>? NY\TWVNlOTJyIN88[{9udA>? MnnCO|IhcA>? NISxU|R{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz MXeyNlgzPTN3NR?=
NCCIT M{fXWWZ2dmO2aX;uJGF{e2G7 MW[xNlAh|rypL33s Mm\tO|IhcA>? NYO2Xllze2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> MYiyNlgzPTN3NR?=
MDA-MB-468 NVjwfZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\LUXQx6oDVMkCwxsDPxGdxbVy= NU\ISZlXOjRiaB?= M3\YXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MV2yNlgyQTF7Nh?=
231-H2N MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPGNQKBmzJyMNMg{txoN22O MWWyOEBp NHjB[W5qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M4\aU|IzQDF7MUm2
A549  NFPzPWRHfW6ldHnvckBCe3OjeR?= M1G3OFIxOC92MECg{txO MV\y[ZN2dHS|IHnuJIEh\G:|ZT3y[ZNxd26|aY\lJIlv[3KnYYPlJIlvKFKRUx?= NYCxZmtWOjJ5N{O2PVc>
A549  NGDne4FHfW6ldHnvckBCe3OjeR?= NH70eYkxNTRyMDFOwG0> Mn75Nk01QCCq MWDjZZV{\XNibX;y[UBufESQQTD0bIFvKG6GTlGg[IFu[Wen M3fJe|IzPzd|Nkm3
A549  Mk[0SpVv[3Srb36gRZN{[Xl? M37KS|ExOCEQvF5CpC=> MmDKNQKBmzR6IHi= MkHyZ4F2e2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u M3TpZVIzPzd|Nkm3
A549  MVTGeY5kfGmxbjDBd5NigQ>? Ml3qNVAxKM7:TdMg M4LXbVDjiJN2ODDo NXvD[JZI[2G3c3XzJHBMTDFiY3zlZZZi\2V? MViyNlc4OzZ7Nx?=
A549  Ml7zSpVv[3Srb36gRZN{[Xl? MlO3NVAxKM7:TdMg MWiw5qCUPDhiaB?= MmPLZ4F2e2W|IH3peI9kcG:wZILpZYwhdG:lYXzpfoF1cW:wIH;mJGJigA>? NFrOTIEzOjd5M{[5Oy=>
A549  MlHlSpVv[3Srb36gRZN{[Xl? MX:xNFAh|ryPwrC= MXiw5qCUPDhiaB?= NXyzRVdb\GWlcnXhd4V{KE2PUDDhcoQhSVSSIHzleoVtew>? NIXzZoczOjd5M{[5Oy=>
MCF-7/Her-18  MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGwMlQzNTF5MECg{txoN22O NWrCUnB{OjRiaB?= MmrubY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4LrclIzPjJzNEC0
MCF-7 NHf0R2VRTFRxUFPJJHRz\WG2bXXueC=> NFnIWHMxNjJ3IN88[{9udC5? NF\XVGgyNTRiaB?= MWHzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 NYnuSmk1OjJ3OUGyPFQ>
MDA-MB-231 NXPjVXBsWESWL2DDTUBVemWjdH3lcpQ> NVPQZZJUOC5{NTFOwIcwdWxw NFfEcHoyNTRiaB?= MYDzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 M1nmblIzPTlzMki0
MDA-MB-235  MmD1VGRVN1CFSTDUdoVifG2nboS= NUTJXY1COC5{NTFOwIcwdWxw MmS1NU01KGh? NFO3Z5N{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 MW[yNlU6OTJ6NB?=
MCF-7 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDzdZBNOC1{IN88[{9udC5? MoDJNlQwPDhiaB?= M{HldGVEPTB;MT6yJO69\y:vTB?= Ml7JNlI2QTF{OES=
NCCIT  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDoS|gzOOLCk{G0NOKh|rypL33s NXnPWZQ4PzJiaB?= MnXmUGQ2OD1zMkFCpO69\y:vbNMg NV3oZo5bOjJ3NkKxOlA>
NCCIT  MYXGeY5kfGmxbjDBd5NigQ>? M4C4S|czKGh? NInnb|J{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOgZYN1cX[rdIpCpC=> MY[yNlU3OjF4MB?=
NCCIT  M1TXS2Z2dmO2aX;uJGF{e2G7 NFq5VlQ4OiCq NFvBTY9{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> M1HrNVIzPTZ{MU[w
NCCIT  NWTM[lFSTnWwY4Tpc44hSXO|YYm= M1;aW|czKGh? M1izZZNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvOTDhZ5Rqfmm2edMg NHLs[2UzOjV4MkG2NC=>
NCCIT  NVK3NoxnTnWwY4Tpc44hSXO|YYm= M4rJbFczKGh? MUnzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NF;acFczOjV4MkG2NC=>
NCCIT  NETGNlBHfW6ldHnvckBCe3OjeR?= MmTDO|IhcA>? MnLMd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGJkdC1{IHPvcpRmdnR? NFnHRmYzOjV4MkG2NC=>
NCCIT  NVrrWpFYTnWwY4Tpc44hSXO|YYm= M2jTNFczKGh? MoLrd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGN6fC2lIHzleoVt NGPwepMzOjV4MkG2NC=>
HeLa NF74OVNHfW6ldHnvckBCe3OjeR?= NXO2Wmw1OzBxN{Cg{txoN22u MWWyOOKhcA>? MXXpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> MXOyNlQ5Pzl|Nx?=
MCF-7  Mnj0SpVv[3Srb36gRZN{[Xl? NFnyb|Y{OC95MDFOwIcwdWx? NIDPR5kzPMLiaB?= NHnXZWZqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? NVLsOXVZOjJ2OEe5N|c>
HeLa MnPxR5l1d3SxeHnjbZR6KEG|c3H5 MlG3N|AwPzBizsznM41t NHnHPFQzPMLiaB?= M1vPbYlv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= NITuWI4zOjR6N{mzOy=>
MCF-7  NFHOe5pEgXSxdH;4bYNqfHliQYPzZZk> MlXxN|AwPzBizsznM41t MY[yOOKhcA>? NV7KSIVbcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt M{H1T|IzPDh5OUO3
NT2 NWe3do1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHkbVlXOTByLU[wNOKh|rypL33s M13DdlI1KGh? NVvjNZlEUUN3ME20NFAhyrWpL33s NG\WVmIzOjR4OUm1Ni=>
NT2 MkKwSpVv[3Srb36gRZN{[Xl? MoTSOFAxyqEQvHevcYw> MWOyOEBp M{np[JNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? MVeyNlQ3QTl3Mh?=
NT2 NUTWRZZsTnWwY4Tpc44hSXO|YYm= NVTlUXRHPDBywrFOwIcwdWx? NWi4OpM{OjRiaB?= MVfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NWntOplxOjJ2Nkm5OVI>
NT2 M1vwemZ2dmO2aX;uJGF{e2G7 M3S3Z|QxOMLizsznM41t M2e0clI1KGh? MnTGd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQnPsMVIhdGW4ZXy= MXyyNlQ3QTl3Mh?=
CHO MkmySpVv[3Srb36gRZN{[Xl? NV3xfGhXOi53wrFOwIcwdWx? NVzNfJFmOThiaD:2JIQ> MX3pcoR2[2W|wrDw[ZJ{cXO2ZX7j[UBw\iClaILvcY9{d22nIHThcYFo\Q>? NXuxZnpLOjJ{M{CxPVU>
Jurkat MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfldHoxNTFyMNMg{txoN22u Mm\zNlQhcA>? NIW0OXNienKnc4TzJJRp\SClZXzsJIN6[2ynIHH0JJRp\SCJMjDwbIF{\Q>? MoP2NlIzOjN|M{K=
Jurkat MVrGeY5kfGmxbjDBd5NigQ>? MUKzNOKh|rypL33s NWT1ZVJtOjRiaB?= MUjpcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKGO7Y3zpcpMhTDNuIFGgZY5lKEJz NFnneokzOjJ{M{OzNi=>
Jurkat NIXDSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTyTIsxNTFyMNMg{txoN22u MnWwNlQhcA>? MmnObY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiYX6gTWM2OCC4YXz1[UBw\iBzMEFOwIcwdUx? MYWyNlIzOzN|Mh?=
Jurkat NUTzV3lZTnWwY4Tpc44hSXO|YYm= NXHWRW1SOzEEoN88[{9udA>? MnzhNlQhcA>? M4rVbIlv[3KnYYPld{B1cGViZX\m[YN1KG:oIID5Z45q\GmxbnWgc44heGixc4Doc5J6dGG2aX;uJIxmfmWuczDv[kBpcXO2b37lJGgzSS6[ MlmzNlIzOjN|M{K=
U2OS EGFPnls NI\ZR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L5OlAuOsLizsznM41t M2T4UVI1KGh? NV[2N|VtcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NUT5[GVCOjF6MUGwNFc>
U2OS KuEnls M{mxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSwMVLDqM7:Zz;tcC=> M2LndVI1KGh? NHT4PYFqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M{TsU|IyQDFzMEC3
MCF-7 NXPENFVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYiwMVQxOCEQvF2= M{PLbFczKGh? NWO4O44{VEN3ME2xOVEvQMLizszN NXTZOpJZOjF5MEOyPVE>
MCF-7/Adr  NXH1[|E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW1R|IxNTRyMDFOwG0> MmLGO|IhcA>? M1\tbGxEPTB;NUiuOeKh|ryPwrC= NE[4cnUzOTdyM{K5NS=>
WI-38 M17iVGZ2dmO2aX;uJGF{e2G7 NUTwTYdlOC92MD:4NQKBkc7:Zz;tcOKh M4m4dFMhcA>? MnXLbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> Ml3lNlE2QTl4MUK=
hBMSC M2HlNmZ2dmO2aX;uJGF{e2G7 NX22OIFQOC92MD:4NQKBkc7:Zz;tcOKh MlnyN{Bp MlrEbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NVPpXWhvOjF3OUm2NVI>
NCI-H23 MVLGeY5kfGmxbjDBd5NigQ>? NVvzeVlYOC92MD:4NQKBkc7:Zz;tcOKh NV7oTYRmOyCq NHnUd4JqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh Mn7nNlE2QTl4MUK=
A-549 NXX3W49bTnWwY4Tpc44hSXO|YYm= MY[wM|QxNzhy4pEJ{txoN22uwrC= MX[zJIg> M1OzfYlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NUfK[W1bOjF3OUm2NVI>
PBL  MULGeY5kfGmxbjDBd5NigQ>? MXKwM|QxNzhy4pEJ{txoN22uwrC= NWHmSZIxOyCq NH;ZS|ZqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MYGyNVU6QTZzMh?=
pol β −/− M37qW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXpU4kxNjJ3LUKwNOKh|rypL33s M1rLfFI1yqCq NVXre5Rk\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li NHfzO4MzOTJ3MUm0OC=>
pol β +/+ MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELCdYIxNjJ3LUKwNOKh|rypL33s NFqzSpczPMLiaB?= NEjLWYdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? MVSyNVI2OTl2NB?=
pol β −/− Mmn0SpVv[3Srb36gRZN{[Xl? NUiydVJ3OC1{LkWg{txoN22u NEHkdGczKGh? MUDjZZV{\XNiRF7BJIRidWGpZR?= Mo\uNlEzPTF7NES=
pol β +/+ MkTLSpVv[3Srb36gRZN{[Xl? M1LSWlAuOi53IN88[{9udA>? NWTkRoVPOiCq NY[4e254[2G3c3XzJGRPSSCmYX3h[4U> MlftNlEzPTF7NES=
pol β −/− MkXUSpVv[3Srb36gRZN{[Xl? M1XVbFAuPSEQvHevcYw> NX2xXnF1PDhiaB?= MVrjZZV{\XNibXnjdo9vfWOuZYXzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= M{\hZlIyOjVzOUS0
pol β +/+ NVvKVHRFTnWwY4Tpc44hSXO|YYm= M{PKWFAuPSEQvHevcYw> NXrrc4hrPDhiaB?= NH3SfmZk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MX2yNVI2OTl2NB?=
TK6  MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCyOU0yPTBizsznM41t NFOzdIw6PiCq NILnW5RqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NF[4VIMzOTB6MUS4Oy=>
TK6  sLUC+Apn1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG3bWUzPS1zNUCg{txoN22u NVPRPXlwQTZiaB?= MmqwbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4P6V|IyODhzNEi3
TK6 sAPE1+Apn1 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fUO|I2NTF3MDFOwIcwdWx? NEj4THI6PiCq MUTzbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4Uh\GWyZX7k[Y51dHl? NFSyVIczOTB6MUS4Oy=>
HCT116 NFTkcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2THb|I2NTF3MDFOwIcwdWx? MkDUPVYhcA>? Mk\ibY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M2K3S|IyODhzNEi3
HCT116 sLUC+Apn1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K2N|I2NTF3MDFOwIcwdWx? MYS5OkBp NELtWFRqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MU[yNVA5OTR6Nx?=
HCT116 sAPE1+Apn1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrSPZozPS1zNUCg{txoN22u NFjBNVM6PiCq NGfsdmp{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= M2TwN|IyODhzNEi3

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LRP6 / Wnt5AB / Dvl2 / β-catenin; 

PubMed: 27649046     


CRL-1490 cells were treated with the indicated concentrations of bleomycin for either 12 or 24 h, and then probed for canonical Wnt proteins LRP6, Wnt5AB, Dvl2, and β-catenin. 

phospho-eIF2α / eIF2α; 

PubMed: 23762310     


Western blotting analysis of phosphorylated, total eIF2α and β-actin in CT26 treated 24 h with the indicated drugs. BLM: Bleomycin

cytochrome c; 

PubMed: 20154224     


mitochondrial release of cytochrome c was detected by Western blot in cytosolic extract and analyzed by band densitometry. Data show the means of four independent experiments ± SE. *Statistical significance from control, P < 0.05. Representative Western blots are shown.

Bcl-xl; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-xL.

Bcl-2; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-2.

27649046 23762310 20154224
Immunofluorescence
LC3; 

PubMed: 23762310     


CT26 cells were cultured on glass slides and treated with indicated drugs for 24 h. The cells were then submitted to anti-LC3 (green) and DAPI (blue) labeling and observed under an epifluorescence microscope. BLM: Bleomycin

23762310
ELISA
HMGB1; 

PubMed: 23762310     


HMGB1 was titrated with ELISA method in supernatant of CT26 cells treated 24 h with indicated drugs. BLM: Bleomycin

23762310
体内研究 Bleomycin sulfate处理后第7天,NOX-/- 的BALf中CD45+细胞是WT的1.7倍多,其中57%为Mf,第21天,在WT中减少到67%,在NOX-/-中减少到83%。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[4]
- 合并
  • Cell lines: ADIPO-P2 细胞
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30分钟
  • Method: ADIPO-P2细胞在D-MEM高葡萄糖培养基中生长,用20%胎牛血清,青霉素(100 U/mL) 和链霉素 (100 μg/mL)增补,在37 °C 和5% CO2大气环境中培养。细胞在包含1.5×105 cells/mL的TC25 Corning培养瓶中单层培养。对于每个实验,建立两个培养瓶,一个用于对照组,一个用于处理培养。在对数生长期,ADIPO-P2细胞用2.5 μg/mL Bleomycin sulfate以30分钟脉冲处理。建立平行对照组,不暴露于Bleomycin sulfate。暴露时间和Bleomycin sulfate浓度根据先前实验室中进行的Bleomycin sulfate处理哺乳动物细胞的研究进行选择。Bleomycin sulfate脉冲处理结束时,细胞用Hank's平衡盐溶液清洗两次,并保存在新鲜培养基中直到采集。处理后5个传代培养期间,将细胞持续保持在培养基中。当培养基中融合(培养基中大约4×105 cells/mL)时,进行传代培养。为估计细胞生长,传代培养时,细胞通过胰蛋白酶化收集,每等份大约200 μL,用0.4%台盼蓝着色,测定活细胞数量。随后细胞悬浮在新鲜培养基中,重新分配到包含1×105 cells/mL的新培养瓶中继续生长。将剩余的细胞丢弃或置于另外的培养瓶中进行细胞遗传学分析,这在处理结束后18小时或第10天进行。为分析染色体突变,培养的最后3小时将colchicine (0.1 μg/mL)加入到细胞培养基。染色体的制备根据标准程序进行。采集后,将细胞低渗震动,固定在甲醇:乙酸(3:1)中,涂布在载玻片上,进行PNA-FISH。进行两个独立的实验。
    (Only for Reference)
动物实验:[7]
- 合并
  • Animal Models: CD-1小鼠
  • Formulation: 生理盐水
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: 鞘内注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 1512.62
化学式

C55H85N17O25S4

CAS号 9041-93-4
储存条件 粉状
溶于溶剂
别名 NSC125066

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate价格 | Bleomycin Sulfate DMSO溶解度 | 采购Bleomycin Sulfate | Bleomycin Sulfate生产 | Bleomycin Sulfate 小鼠 | Bleomycin Sulfate化学结构 | Bleomycin Sulfate分子量 | Bleomycin Sulfate molecular weight | Bleomycin Sulfate说明书 | Bleomycin Sulfate供应商 | Bleomycin Sulfate体内 | Bleomycin Sulfate细胞系 | Bleomycin Sulfate浓度 | Bleomycin Sulfate nmr | Bleomycin Sulfate核磁 | Bleomycin Sulfate半数抑制浓度 | Bleomycin Sulfate体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID